In China's vitamin, fine chemicals, and pharmaceutical industries, three closely connected companies have quietly established themselves among the industry's leading players through an integrated value chain and long-term strategic development. They are Brother Enterprises Holding Co., Ltd., Jiangsu Brother Vitamins Co., Ltd., and Jiangxi Brother Pharmaceutical Co., Ltd.
For many industry professionals and international buyers, these similarly named companies can be confusing at first glance. Although they share the same corporate heritage, each serves a distinct role within the Brother Technology ecosystem. Together, they form a complete industrial network spanning strategic investment, vitamin manufacturing, and high-value pharmaceutical production.
This article explores how these three companies are connected, what differentiates their businesses, and why their coordinated development has become a competitive advantage in the global fine chemical and pharmaceutical markets.
All three companies belong to the Brother Technology industrial system and operate under a clear organizational structure consisting of a strategic holding company supported by two specialized manufacturing bases.
As the group's holding company, Brother Enterprises Holding Co., Ltd. is responsible for corporate strategy, investment, financing, capital management, global resource allocation, and long-term business planning. Rather than engaging directly in manufacturing, it oversees the development of the group's industrial operations, including infrastructure investment, capacity expansion, supply chain coordination, regulatory compliance, and risk management across both the Jiangsu and Jiangxi production bases.
Through centralized management, the holding company is able to coordinate major R&D investments, optimize global raw material procurement, strengthen capital market operations, and improve overall operational efficiency, providing the strategic foundation for the group's sustainable growth.
Established in May 2005 and located in Dafeng Marine Economic Development Zone, Yancheng, Jiangsu Province, Jiangsu Brother Vitamins Co., Ltd. serves as the group's long-established vitamin production base and is a wholly owned subsidiary of Brother Technology.
If the holding company represents the group's strategic headquarters, Jiangsu Brother Vitamins forms the industrial backbone of the organization.
For more than two decades, the company has specialized in vitamin manufacturing, focusing primarily on Vitamin B1, Vitamin B3, and Vitamin K3. Its products are widely used in feed additives, food additives, and pharmaceutical intermediates. Recognized as both a National High-Tech Enterprise and a "Little Giant" Specialized and Innovative Enterprise, the company emphasizes large-scale production, cost efficiency, and reliable global supply.
Compared with the group's pharmaceutical operations, the Jiangsu facility concentrates on high-volume vitamin manufacturing, serving major feed and food companies worldwide while providing a stable source of revenue for the group.
Founded in 2014 in Pengze County, Jiangxi Province, Jiangxi Brother Pharmaceutical Co., Ltd. occupies an industrial park covering approximately 2,000 acres and serves as the group's advanced pharmaceutical manufacturing base. It is also a wholly owned subsidiary of Brother Technology.
While the Jiangsu facility focuses on large-scale vitamin production, Jiangxi Brother Pharmaceutical targets high-value pharmaceutical and specialty chemical markets. Its business portfolio includes premium vitamin derivatives, flavor and fragrance ingredients, iodinated contrast media, specialty APIs, and chemical catalysts.
Supported by Jiangxi's integrated chemical industry infrastructure, the company has earned multiple recognitions, including National Green Factory status, Provincial Enterprise Technology Center certification, and a Provincial Academician Workstation. Combining advanced manufacturing with sustainable production practices, the company achieved operating revenue exceeding RMB 1.656 billion in 2025 and employs more than 1,700 people, making it a key platform for Brother Technology's transformation toward innovation-driven pharmaceutical manufacturing.
Many chemical manufacturers focus either on commodity chemicals or pharmaceutical products, often resulting in fragmented supply chains and higher production costs.
The Brother group adopts a different approach by assigning distinct responsibilities to each business entity while integrating them into a unified industrial ecosystem.
In simple terms, Jiangsu manufactures the foundational materials, Jiangxi produces high-value pharmaceutical products, and the holding company coordinates the group's overall development.
This integrated model enables greater raw material security, optimized production costs, stronger technical collaboration, and improved resilience against market volatility and supply chain disruptions.
Success in both fine chemicals and pharmaceuticals depends not only on production capacity but also on continuous technological innovation.
The three companies share a unified research and development system consisting of a corporate research institute, specialized business-unit R&D centers, and technical teams located within each manufacturing facility.
The group collaborates extensively with leading research institutions, including Tsinghua University, Zhejiang University, Sichuan University, and the Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, among many others. These partnerships focus on advanced synthesis technologies, green catalytic processes, pharmaceutical purification techniques, and sustainable manufacturing.
At the same time, the two manufacturing bases maintain distinct research priorities.
The Jiangsu facility focuses on improving vitamin production efficiency, reducing manufacturing costs, and optimizing large-scale industrial processes.
The Jiangxi facility concentrates on pharmaceutical intermediates, iodinated contrast media, innovative APIs, environmentally friendly production technologies, and regulatory compliance for global pharmaceutical markets.
By sharing research resources while specializing in different technological directions, the group minimizes duplication, accelerates innovation, and supports its transition from a traditional chemical manufacturer to a modern innovation-oriented pharmaceutical enterprise.
Within the chemical and pharmaceutical industries, companies with similar names often exist because of corporate restructuring, tax planning, or business separation, frequently creating confusion among customers.
The Brother group's organizational strategy offers a valuable example of how specialization and integration can work together.
First, each company maintains a clearly defined business focus, separating strategic management, bulk manufacturing, and high-value pharmaceutical production to improve operational efficiency and regulatory compliance.
Second, vertical integration across the supply chain strengthens internal collaboration while reducing exposure to raw material price fluctuations and supply chain risks.
Third, the group balances stable revenue from mature vitamin businesses with long-term investment in innovative pharmaceutical products, supporting both short-term profitability and sustainable growth.
Beginning with the establishment of the Jiangsu vitamin manufacturing base in 2005, followed by the development of the holding platform and the launch of the Jiangxi pharmaceutical facility nearly a decade later, the Brother group has evolved from a single vitamin manufacturer into a diversified pharmaceutical and fine chemical enterprise with a fully integrated industrial ecosystem.
Although the three companies operate independently, they are strategically connected through shared technology, coordinated management, and complementary business objectives.
The global chemical and pharmaceutical industries are filled with companies that share similar names, but few possess such a clearly defined division of responsibilities and such an effectively integrated industrial structure.
Brother Enterprises Holding Co., Ltd., Jiangsu Brother Vitamins Co., Ltd., and Jiangxi Brother Pharmaceutical Co., Ltd. represent three companies, three strategic locations, and one unified vision for long-term industrial development.
As global demand continues to grow for vitamins, food ingredients, specialty chemicals, and pharmaceutical APIs, the Brother group is well positioned to leverage its integrated supply chain, advanced manufacturing capabilities, and strong R&D foundation. With its commitment to innovation and quality, this quietly expanding Chinese enterprise is poised to become an increasingly influential force in the global vitamin and specialty pharmaceutical industries.
Mobile: +8615371019725
E-mail: sales7@bouling-chem.com
Website: www.brother-pharmaceutical.com
Copyright © Jiangxi Brother Pharmaceutical Co., Ltd. 2026. All right reserved.
